Inhibition of lung adenocarcinoma cells by insulin-like growth factor-I receptor and Kirsten rat sarcoma mutations: A mutation analysis with antisense oligodeoxynucleotide.

about

Inhibition of lung adenocarcinoma cells by insulin-like growth factor-I receptor and Kirsten rat sarcoma mutations: A mutation analysis with antisense oligodeoxynucleotide.

Item

http://www.wikidata.org/entity/Q35663425

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Inhibition of lung adenocarcin ...... ntisense oligodeoxynucleotide.

@ast

Inhibition of lung adenocarcin ...... ntisense oligodeoxynucleotide.

@en

type

Item

label

Inhibition of lung adenocarcin ...... ntisense oligodeoxynucleotide.

@ast

Inhibition of lung adenocarcin ...... ntisense oligodeoxynucleotide.

@en

prefLabel

Inhibition of lung adenocarcin ...... ntisense oligodeoxynucleotide.

@ast

Inhibition of lung adenocarcin ...... ntisense oligodeoxynucleotide.

@en

P1476

Inhibition of lung adenocarcin ...... ntisense oligodeoxynucleotide.

@en

P2093

Jiahui Zhang

http://www.w3.org/2001/XMLSchema#string

Lei Zhao

http://www.w3.org/2001/XMLSchema#string

Peng Du

http://www.w3.org/2001/XMLSchema#string

Shaoming Li

http://www.w3.org/2001/XMLSchema#string

Zhiqiang Zou

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition

Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizo

Type I insulin-like growth factor receptor induces pulmonary tumorigenesis.

Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers.

Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development.

The genetics and biology of KRAS in lung cancer.

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions.

EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.

Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.

P304

260-268

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1759-7714.12176

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26273371

http://www.w3.org/2001/XMLSchema#string

P932

4448390

http://www.w3.org/2001/XMLSchema#string